KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Ginkgo Bioworks Holdings (DNA) over the last 6 years, with Q2 2025 value amounting to $38000.0.

  • Ginkgo Bioworks Holdings' Capital Expenditures fell 9985.94% to $38000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year decrease of 5912.16%. This contributed to the annual value of $62.5 million for FY2024, which is 5328.3% up from last year.
  • Per Ginkgo Bioworks Holdings' latest filing, its Capital Expenditures stood at $38000.0 for Q2 2025, which was down 9985.94% from $7.6 million recorded in Q1 2025.
  • In the past 5 years, Ginkgo Bioworks Holdings' Capital Expenditures registered a high of $27.0 million during Q2 2024, and its lowest value of $38000.0 during Q2 2025.
  • For the 5-year period, Ginkgo Bioworks Holdings' Capital Expenditures averaged around $12.2 million, with its median value being $11.5 million (2022).
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 44304.47% in 2023, then tumbled by 9985.94% in 2025.
  • Quarter analysis of 5 years shows Ginkgo Bioworks Holdings' Capital Expenditures stood at $5.1 million in 2021, then surged by 401.47% to $25.6 million in 2022, then tumbled by 86.56% to $3.4 million in 2023, then soared by 297.85% to $13.7 million in 2024, then crashed by 99.72% to $38000.0 in 2025.
  • Its Capital Expenditures stands at $38000.0 for Q2 2025, versus $7.6 million for Q1 2025 and $13.7 million for Q4 2024.